G. A. Gulin

G. A. Gulin

Auto-generated profile, based on publicly available information

G. A. Gulin

“European medical center UGMK-Health” Ltd.; Sverdlovsk Region Onсology Center

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2020 in Cancer Urology
Verified
Journal Article
Open access
PDF file
NRN. A. Rubtsova
N. A. Rubtsova
AMA. V. Mishchenko
A. V. Mishchenko
VDV. V. Danilov
V. V. Danilov
GGG. A. Gulin
G. A. Gulin
BAB. Ya. Alekseev
B. Ya. Alekseev
AKAndrei Kaprin
Andrei Kaprin
Previously presented Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) system was developed on the basis of consensus that was achieved by the results of published studies containing expert and analytical conclusions. Numerous studies on PI-RADS v2, not only confirmed the importance of a unified system in the diagnosis of prostate cancer, but also revealed a number of limitations. In order to eliminate flaws of PI-RADS v2, a number of potential solutions were proposed. The PI-RADS Steering Committee recommended changes in PI-RADS v2, with maintaining the structure of sequence scoring and using these scores to obtain the final category. The updated version was published as PI-RADS v2.1 at the beginning of 2019. It is expected that the use of PI-RADS v2.1 will optimize and simplify the evaluation magnetic resonance imaging of prostate and reduce the number of interpretation errors. At the same time, it is necessary to continue further studies on the assessment of the clinical significance of this system when choosing a treatment strategy and monitoring patients with a high potentialfor the development

18 May 2021 in Medical Visualization
Verified
Journal Article
Closed access
PDF file
GGG. A. Gulin
G. A. Gulin
AZA. V. Zyryanov
A. V. Zyryanov
NRN. A. Rubtsova
N. A. Rubtsova
VAV. M. Artyemov
V. M. Artyemov
AZA. V. Zamyatin
A. V. Zamyatin
EGE. A. Grebenev
E. A. Grebenev
Multiparametric MRI (mpMRI) has superb sensitivity in prostate cancer detection. mpMRI is increasingly used not only for primary diagnostics, but for location of suspicious lesion before biopsy in case of targeted biopsy (TB). In many recent studies have been shown higher level of TB accuracy in prostate cancer detection in comparison with traditional systemic biopsy. In recent EAU, NICE, ACR recommendations mpMRI is indicated for men with high level of prostate cancer suspicion with previous negative results of systemic biopsy. However, it is not absolutely clear, whether mpMRI is indicated for biopsy-naïve men. This study is dedicated for prostate biopsy planning in the groups of biopsy-naïve men and with the history of previous biopsy.

30 September 2020 in Cancer Urology
Verified
Journal Article
Open access
PDF file
AZA. V. Zyryanov
A. V. Zyryanov
GGG. A. Gulin
G. A. Gulin
NRN. A. Rubtsova
N. A. Rubtsova
VMV. O. Mager
V. O. Mager
APA. E. Putintsev
A. E. Putintsev
DKD. D. Kuznetsova
D. D. Kuznetsova
Background. Targeted biopsy is proposed as a method of choice in the algorithm of prostate cancer diagnosis, but not all the features of method has been evaluated.Objective: determine the rational number of targeted biopsy samples in patients with clinically significant prostate cancer.Materials and methods. The magnetic resonance imaging and fusion biopsy data of 156 patients with suspected prostate cancer were retrospectively evaluated.Results and conclusion. In the study statistically significant dependence of the positive histological results in patients with clinically significant prostate cancer from the number of biopsy samples was found. The potential probability of a false negative histological examination with an insufficient number of biopsy samples was noted. These results confirm the latest published data of potential targeted biopsy false in true positive patients after multiparametric magnetic resonance imaging. An increase in the number of biopsy samples in the target lesion reduces the likelihood of false-negative results. The main causes of such discrepancy are some technical laxity and the heterogeneous histological structure of prostate cancer. Increase the number of biopsy cores can reduce the likelihood of false-negative results.